Equity Brief: Ratings Changes for November 28th: SXE, SXE, TFM, TIVO, UTI, VE, VIVO, VNO, VOLC

A number of stocks were upgraded and downgraded by equities research analysts today, as reported by Analyst Ratings Network (http://bit.ly/equitybriefdaily) and Equity Brief:

Robert W. Baird initiated coverage on shares of Southcross Energy Partners LP SXE. They issued an outperform rating on the stock and set a $26.00 price target.

Stifel Nicolaus initiated coverage on shares of Southcross Energy Partners LP SXE. They issued a buy rating on the stock and set a $25.00 price target.

JPMorgan Chase initiated coverage on shares of Southcross Energy Partners LP SXE. They issued an overweight rating on the stock and set a $27.00 price target.

Citigroup initiated coverage on shares of Southcross Energy Partners LP SXE. They issued a buy rating on the stock and set a $26.00 price target.

Barclays Capital initiated coverage on shares of Southcross Energy Partners LP SXE. They issued an overweight rating on the stock and set a $27.00 price target.

Raymond James initiated coverage on shares of Southcross Energy Partners LP SXE. They issued an outperform rating on the stock.

Deutsche Bank downgraded shares of The Fresh Market Inc TFM from a buy rating to a hold rating.

Jefferies Group raised its price target on shares of TiVo Inc TIVO from $14.00 to $15.00. They have a buy rating on the stock.

BMO Capital Markets downgraded shares of Universal Technical Institute UTI from a market perform rating to an underperform rating.

HSBC upgraded shares of Veolia Environnement VE from a neutral rating to an overweight rating.

Wedbush downgraded shares of Meridian Bioscience, Inc. (VIVO) from a neutral rating to an underperform rating. Their analysts now have a $17.00 price target on the stock.

Citigroup upgraded shares of Vornado Realty Trust (VNO) from a neutral rating to a buy rating. Citigroup now has a $85.00 price target on the stock, up previously from $82.00.

Zacks reiterated its neutral rating on shares of Volcano (VOLC). They have a $28.00 price target on the stock. Zacks' analyst wrote, "Volcano's third quarter performance was mixed with EPS of $0.04 lagging the year-ago $0.05 but in line with the Zacks Consensus Estimate. Revenues of $93.7 million were up 12% at CER but missed the consensus of $95 million. Meanwhile, we are impressed with the company's pipeline development, of which many products are slated for release over the next few quarters. We also believe that favorable industry trends should aid the growth of the company. At present clinicians and hospitals are facing increasing pressure to justify the medical necessity of PCI therapy. However, several challenges currently at play forced the company to lower its 2012 outlook. Moreover, margins still remain under pressure. Although the situation is set to improve by year end, amidst tough competitive landscape, we maintain our Neutral recommendation on the stock. "

Argus downgraded shares of Vertex Pharmaceuticals (VRTX) from a buy rating to a hold rating.

Stay on top of analysts' coverage with Analyst Ratings Network's free daily email newsletter that provides a concise list of analysts' upgrades, downgrades and initiations. Register at http://bit.ly/equitybriefdaily

Content and Media Contact: newseditor@equitybrief.net